A Single Arm, Open-label Multicenter Phase II Trial of Temsirolimus in Patients With Relapsed/Recurrent Squamous Cell Cancer of the Head and Neck (HNSCC).

Trial Profile

A Single Arm, Open-label Multicenter Phase II Trial of Temsirolimus in Patients With Relapsed/Recurrent Squamous Cell Cancer of the Head and Neck (HNSCC).

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Dec 2014

At a glance

  • Drugs Temsirolimus (Primary)
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Acronyms TEMHEAD
  • Most Recent Events

    • 07 Jul 2012 Status changed from recruiting to completed as reported in the European Clinical Trials Database record.
    • 07 Jul 2012 Pfizer added as associations as reported in the European Clinical Trials Database record.
    • 16 Nov 2011 Actual initiation date changed from Jun 2010 to 9 Feb 2010 as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top